Rivaroxaban: Expanded Role in Cardiovascular Disease Management-A Literature Review.

Tytuł:: Rivaroxaban: Expanded Role in Cardiovascular Disease Management-A Literature Review.
Autorzy:: Ajmal M; University of Arizona, College of Medicine, Tucson, AZ, USA.
Friedman J; University of Arizona, College of Medicine, Tucson, AZ, USA.
Sipra QUAR; University of Arizona, College of Medicine, Tucson, AZ, USA.
Lassar T; University of Arizona, College of Medicine, Tucson, AZ, USA.
Źródło:: Cardiovascular therapeutics [Cardiovasc Ther] 2021 Jan 08; Vol. 2021, pp. 8886210. Date of Electronic Publication: 2021 Jan 08 (Print Publication: 2021).
Typ publikacji:: Journal Article; Review
Język:: English
Imprint Name(s):: Publication: 2019- : [London, United Kingdom] : Hindawi
Original Publication: Oxford : Wiley-Blackwell, c2008-c2018.
MeSH Terms:: Cardiovascular Diseases/*drug therapy
Factor Xa Inhibitors/*administration & dosage
Rivaroxaban/*administration & dosage
Cardiovascular Diseases/diagnosis ; Clinical Decision-Making ; Factor Xa Inhibitors/adverse effects ; Hemorrhage/chemically induced ; Humans ; Patient Selection ; Risk Factors ; Rivaroxaban/adverse effects ; Treatment Outcome
References:: J Clin Oncol. 2018 Jul 10;36(20):2017-2023. (PMID: 29746227)
JAMA Cardiol. 2020 Jun 1;5(6):685-692. (PMID: 32320043)
J Thromb Haemost. 2015 Sep;13(9):1590-6. (PMID: 26179293)
Stroke. 2014 Sep;45(9):2805-7. (PMID: 25082810)
Am J Hematol. 2019 Jun;94(6):697-709. (PMID: 30916798)
Thromb Res. 2019 Aug;180:37-42. (PMID: 31200341)
N Engl J Med. 2012 Apr 5;366(14):1287-97. (PMID: 22449293)
N Engl J Med. 2017 Oct 5;377(14):1319-1330. (PMID: 28844192)
Chest. 2015 Feb;147(2):475-483. (PMID: 25211264)
Eur Heart J. 2013 Jun;34(22):1670-80. (PMID: 23470494)
N Engl J Med. 2013 Feb 7;368(6):513-23. (PMID: 23388003)
Am J Med. 2016 Apr;129(4):392-7. (PMID: 26551984)
N Engl J Med. 2008 Jun 26;358(26):2765-75. (PMID: 18579811)
Lancet. 2009 May 16;373(9676):1673-80. (PMID: 19411100)
Int J Cardiol. 2018 Nov 1;270:54-59. (PMID: 30220379)
J Stroke Cerebrovasc Dis. 2020 Apr;29(4):104685. (PMID: 32057654)
Pharmacoeconomics. 2012 Feb 1;30(2):87-101. (PMID: 22187932)
J Thromb Haemost. 2016 Jun;14(6):1308-13. (PMID: 27299806)
Cardiovasc Drugs Ther. 2019 Jun;33(3):331-337. (PMID: 30888571)
N Engl J Med. 2008 Jun 26;358(26):2776-86. (PMID: 18579812)
J Am Coll Cardiol. 2020 Mar 24;75(11):1299-1308. (PMID: 32192656)
N Engl J Med. 2018 Feb 22;378(8):699-707. (PMID: 29466159)
N Engl J Med. 2010 Dec 23;363(26):2499-510. (PMID: 21128814)
J Am Coll Cardiol. 2019 Jul 9;74(1):104-132. (PMID: 30703431)
Chest. 2012 Feb;141(2 Suppl):e278S-e325S. (PMID: 22315265)
Lancet. 2008 Jul 5;372(9632):31-9. (PMID: 18582928)
Curr Pharm Des. 2018;24(38):4516-4517. (PMID: 30621559)
Am J Cardiol. 2019 Aug 1;124(3):367-372. (PMID: 31126539)
Medicine (Baltimore). 2019 Mar;98(9):e14539. (PMID: 30817570)
Blood. 2008 Sep 15;112(6):2242-7. (PMID: 18621928)
Med Clin North Am. 2019 Sep;103(5):847-862. (PMID: 31378330)
Chest. 2004 Sep;126(3 Suppl):338S-400S. (PMID: 15383478)
Acad Emerg Med. 2018 Sep;25(9):995-1003. (PMID: 29757489)
PLoS One. 2015 Dec 30;10(12):e0144856. (PMID: 26716830)
Sao Paulo Med J. 2016 Jul-Sep;134(4):322-9. (PMID: 27581333)
Int J Cardiol. 2013 Sep 1;167(5):1772-82. (PMID: 23298559)
N Engl J Med. 2018 Oct 4;379(14):1332-1342. (PMID: 30146935)
Rev Port Cardiol. 2012 Apr;31 Suppl 1:45-50. (PMID: 22541035)
Unfallchirurg. 2010 Nov;113(11):908-14. (PMID: 21069508)
Int J Cardiol. 2019 May 1;282:53-58. (PMID: 30518479)
Emerg Med Clin North Am. 2017 Nov;35(4):743-770. (PMID: 28987427)
Clin Pharmacokinet. 2014 Jan;53(1):1-16. (PMID: 23999929)
J Med Econ. 2017 Aug;20(8):813-824. (PMID: 28521540)
Drugs. 2012 Sep 10;72(13):1755-64. (PMID: 22876779)
Am J Emerg Med. 2016 Jan;34(1):116.e3-4. (PMID: 26081413)
Circulation. 1994 Jul;90(1):61-8. (PMID: 8026047)
Arch Med Sci Atheroscler Dis. 2017 Dec 31;2:e108-e112. (PMID: 29379891)
Br J Clin Pharmacol. 2013 Sep;76(3):455-66. (PMID: 23305158)
N Engl J Med. 2019 Apr 4;380(14):1326-1335. (PMID: 30730782)
Circulation. 2014 Jun 10;129(23):2440-92. (PMID: 24589852)
Vasc Health Risk Manag. 2015 Jan 30;11:117-23. (PMID: 25673997)
N Engl J Med. 2012 Jan 5;366(1):9-19. (PMID: 22077192)
Heart Lung Circ. 2017 Sep;26(9):911-917. (PMID: 28684097)
Clin Pharmacokinet. 2013 Apr;52(4):243-54. (PMID: 23389892)
Heart Fail Rev. 2020 Mar;25(2):207-216. (PMID: 31256317)
BMJ. 2017 Nov 28;359:j5058. (PMID: 29183961)
J Thromb Haemost. 2018 Jun;16(6):1028-1039. (PMID: 29624847)
Clin J Am Soc Nephrol. 2019 Feb 7;14(2):278-287. (PMID: 29802125)
Drugs R D. 2018 Dec;18(4):303-308. (PMID: 30293126)
J Clin Med. 2020 Apr 02;9(4):. (PMID: 32252423)
N Engl J Med. 2020 Jan 9;382(2):120-129. (PMID: 31733180)
Lancet. 2009 Jul 4;374(9683):29-38. (PMID: 19539361)
Cardiovasc Ther. 2020 Jun 23;2020:3057168. (PMID: 32695228)
N Engl J Med. 2017 Mar 30;376(13):1211-1222. (PMID: 28316279)
Vasc Health Risk Manag. 2018 Jan 09;14:13-21. (PMID: 29391805)
JAMA. 2010 Sep 22;304(12):1350-7. (PMID: 20805624)
Nephrol Dial Transplant. 2019 Feb 1;34(2):265-277. (PMID: 29509922)
Clin Cardiol. 2021 Jan;44(1):20-26. (PMID: 33219708)
Clin Gastroenterol Hepatol. 2017 Nov;15(11):1674-1683.e3. (PMID: 28458008)
Circulation. 2007 Jul 10;116(2):180-7. (PMID: 17576867)
Clin Cardiol. 2015 Dec;38(12):720-4. (PMID: 26467851)
N Engl J Med. 2011 Sep 8;365(10):883-91. (PMID: 21830957)
Eur J Health Econ. 2018 Sep;19(7):957-965. (PMID: 29181817)
Ann Intern Med. 2019 Nov 19;171(10):685-694. (PMID: 31610549)
Clin Drug Investig. 2017 Sep;37(9):833-844. (PMID: 28608312)
Med Clin North Am. 2019 May;103(3):549-564. (PMID: 30955521)
J Am Coll Cardiol. 2014 Dec 2;64(21):e1-76. (PMID: 24685669)
Eur Heart J. 2020 Jan 21;41(4):509-518. (PMID: 31120118)
N Engl J Med. 2018 Sep 20;379(12):1118-1127. (PMID: 30145946)
Stroke. 2017 Sep;48(9):2494-2503. (PMID: 28716982)
Substance Nomenclature:: 0 (Factor Xa Inhibitors)
9NDF7JZ4M3 (Rivaroxaban)
Entry Date(s):: Date Created: 20210128 Date Completed: 20210209 Latest Revision: 20210209
Update Code:: 20240105
PubMed Central ID:: PMC7810545
DOI:: 10.1155/2021/8886210
PMID:: 33505518
: Czasopismo naukowe

Pełny tekst

Direct oral anticoagulants (DOACs) are widely used for the prevention of stroke in nonvalvular atrial fibrillation, treatment of deep venous thrombosis and pulmonary embolism, and as prophylaxis after hip and knee surgery after approval by the Food and Drug Administration. In the last decade, DOACs were studied for various indications; this review is focused on rivaroxaban, a factor Xa inhibitor, which is used in an expanded evidence-based fashion for coronary artery disease, peripheral artery disease, heart failure, malignancy, and prophylaxis of deep venous thrombosis in acute medical illnesses.
Competing Interests: The authors declare that they have no conflicts of interest.
(Copyright © 2021 Muhammad Ajmal et al.)

Zaloguj się, aby uzyskać dostęp do pełnego tekstu.

Informacja